{"id":710079,"date":"2026-04-07T02:55:36","date_gmt":"2026-04-07T02:55:36","guid":{"rendered":"https:\/\/www.europesays.com\/us\/710079\/"},"modified":"2026-04-07T02:55:36","modified_gmt":"2026-04-07T02:55:36","slug":"fda-approves-eli-lillys-new-weight-loss-pill-with-no-food-restrictions","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/710079\/","title":{"rendered":"FDA approves Eli Lilly’s new weight loss pill with no food restrictions"},"content":{"rendered":"\n

The Food and Drug Administration approved Eli Lilly’s new oral weight loss drug Foundayo, the company said<\/a> Wednesday, making it the market’s only GLP-1 pill that can be taken at any time of day without restrictions on food or water.<\/p>\n

The drug, generically known as orforglipron, will be sold as a once-daily tablet. Lilly said it will first launch through LillyDirect before rolling out to traditional pharmacies and telehealth platforms in the weeks that follow.<\/p>\n

For those without insurance, the monthly price varies by dosage tier, running anywhere from $149 to $349. Lilly is offering a coupon that could bring monthly out-of-pocket costs down to $25 for commercially insured patients.<\/p>\n

In the ATTAIN-1 Phase 3 trial, participants who remained on the highest dose of Foundayo lost an average of 27.3 pounds, or 12.4% of body weight, compared with 2.2 pounds for those on placebo. The trial enrolled more than 3,100 participants across multiple countries over 72 weeks.<\/p>\n

Unlike injectable GLP-1 therapies such as Zepbound, which require complex production methods, Foundayo belongs to a class of small molecules that are easier to manufacture and scale worldwide, Eli Lilly CEO Dave Ricks told CNBC<\/a>. Ricks said the company has sought clearance from regulators in dozens of countries ahead of a wider global release.<\/p>\n

The drug’s FDA approval positions it as a direct competitor to Novo Nordisk’s Wegovy pill, which exceeded 600,000 prescriptions in March, according to CNBC. The two companies matched each other on entry-level pricing, setting their lowest dose at $149 a month for uninsured patients following an agreement with the Trump administration.<\/p>\n

Foundayo’s clinical weight loss performance, at about 12.4% of body weight, trails the roughly 16.6% reduction Novo’s pill achieved in its own late-stage study. By contrast, Wegovy’s pill comes with strict intake instructions, requiring patients to fast and limit their water intake before taking it at the start of their day.<\/p>\n

“We want people to be on the medicine that meets their health goals,” Ricks said. “If it has Lilly on the box, that’s the goal we have.”<\/p>\n

FactSet consensus figures reported by CNBC project the drug will bring in $14.79 billion annually within five years, roughly half the $24.68 billion forecast for Lilly’s injectable Zepbound.<\/p>\n

Foundayo carries warnings including a potential risk of thyroid tumors and thyroid cancer. The most common side effects include constipation, diarrhea, headache, nausea, and vomiting.<\/p>\n","protected":false},"excerpt":{"rendered":"The Food and Drug Administration approved Eli Lilly’s new oral weight loss drug Foundayo, the company said Wednesday,…\n","protected":false},"author":3,"featured_media":710080,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[34],"tags":[188502,25996,6434,210,1060,24755,67,132,68,111779,428,4636],"class_list":["post-710079","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-body-weight","tag-eli-lilly","tag-food-and-drug-administration","tag-health","tag-medication","tag-pill","tag-united-states","tag-unitedstates","tag-us","tag-water-intake","tag-weight-loss","tag-weight-loss-drug"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116361175157646571","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/710079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=710079"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/710079\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/710080"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=710079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=710079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=710079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}